881844-09-3

Basic information

• Product Name: N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine
• Synonyms: N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine;4-PyridinaMine, 2-chloro-N-[(4-Methoxyphenyl)Methyl]-3-nitro-;2-chloro-N-(4-Methoxybenzyl)-3-nitropyridin-4-aMine;N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine-3
• CAS NO: 881844-09-3
• Molecular Formula: C₁₃H₁₂ClN₃O₃
• Molecular Weight: 293.70568
• Mol File: 881844-09-3.mol

Chemical Properties

• Melting Point: 106 °C
• Boiling Point: 469.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.394±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 0.18±0.10(Predicted)
• CAS DataBase Reference: N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine(881844-09-3)
• EPA Substance Registry System: N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine(881844-09-3)

Safety Data

• Hazardous Substances Data: 881844-09-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine is used as a research compound for the development of new pharmaceutical agents. Its unique structure and functional groups may contribute to the discovery of novel therapeutic agents with specific biological activities.
Used in Chemical Research:
In the field of chemical research, N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine serves as a starting material or intermediate in the synthesis of various organic compounds. Its versatile structure allows for further functionalization and modification, enabling the exploration of new chemical reactions and the creation of new molecules with potential applications.
Used in Drug Development:
N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine is used as a lead compound in drug development. Its unique structure may possess specific biological activities that can be optimized and fine-tuned through medicinal chemistry approaches to develop effective drugs for various therapeutic areas.
It is crucial to handle and utilize N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine with care, adhering to all necessary safety protocols and regulations to ensure proper handling and avoid potential hazards. This includes appropriate storage, handling, and disposal practices, as well as the use of personal protective equipment when working with this chemical compound.

Upstream product

• 89282-12-2 2,4-dihydroxy-3-nitropyridine 
• 5975-12-2 2,4-dichloro-3-nitro-pyridine 
• 2393-23-9 4-methoxy-benzylamine 

Downstream Products

• 1061317-31-4 2-(7-iodo-2,3-dihydrobenzo[b][1,4]dioxin-6-ylthio)-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridin-4-amine 
• 1012059-57-2 2-((6-iodobenzo[d][1,3]dioxol-5-yl)thio)-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridin-4-amine 
• 1012059-50-5 4-amino-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridine-2(3H)-thione 
• 1012059-49-2 4-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridine-2(3H)-thione 
• 1012059-50-5 4-amino-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridine-2-thiol 
• 1012059-49-2 4-Chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridine-2-thiol 
• 1012059-54-9 2-(6-bromobenzo[d][1,3]dioxol-5-ylthio)-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridin-4-amine 
• 881844-10-6 2-chloro-N⁴-(4-methoxybenzyl)pyridine-3,4-diamine 
• 6811-77-4 3-deazaadenine 
• 881844-18-4 4-amino-3-[2'-deoxy-3',5'-di-O-(4-toluoyl)-β-D-erythro-pentofuranosyl]-7-nitro-3H-imidazo[4,5-c]pyridine 
• 881844-13-9 4-amino-1-[2'-deoxy-3',5'-di-O-(4-toluoyl)-β-D-erythro-pentofuranosyl]-7-nitro-1H-imidazo[4,5-c]pyridine 
• 881844-11-7 4-chloro-1-(p-methoxybenzyl)-1H-imidazo[4,5-c]pyridine 
• 881844-12-8 4-(isobutyrylamino)-1H-imidazo[4,5-c]pyridine 
• 3243-26-3 4-hydrazino-1H-imidazo[4,5-c]pyridine 

Relevant articles and documents

Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and in Vivo Efficacy in the Plasmodium falciparum NSG Mouse Model

A series of 2,4-disubstituted imidazopyridines, originating from a SoftFocus Kinase library, was identified from a high throughput phenotypic screen against the human malaria parasite Plasmodium falciparum. Hit compounds showed moderate asexual blood stage activity. During lead optimization, several issues were flagged such as cross-resistance against the multidrug-resistant K1 strain, in vitro cytotoxicity, and cardiotoxicity and were addressed through structure-Activity and structure-property relationship studies. Pharmacokinetic properties were assessed in mice for compounds showing desirable in vitro activity, a selectivity window over cytotoxicity, and microsomal metabolic stability. Frontrunner compound 37 showed good exposure in mice combined with good in vitro activity against the malaria parasite, which translated into in vivo efficacy in the P. falciparum NOD-scid IL-2Rnull (NSG) mouse model. Preliminary mechanistic studies suggest inhibition of hemozoin formation as a contributing mode of action.

Fused Amino Pyridines for the Treatment of Lung Cancer

The present invention relates to the use of compounds with fused amino pyridine core for the treatment of malignancies associated with brain and lung. The oral administration of compounds of the instant application results in effective brain penetration and provides for non-intrusive treatment of brain and lung tumors.

Therapeutic compounds and uses thereof

The invention provides novel therapeutic compounds, pharmaceutical compositions comprising these compounds, and methods for using these compounds and compositions to treat diseases and disorders such as cancer.

FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS

The present invention relates to the use of compounds with fused amino pyridine core for the treatment of malignancies associated with brain and lung. The oral administration of compounds of the instant application results in effective brain penetration and provides for non-intrusive treatment of brain and lung tumors.

HSP90 Inhibitors Containing a Zinc Binding Moiety

The present invention relates to HSP90 inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors.

FUSED AMINO PYRIDINE AS HSP90 INHIBITORS

The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.

Synthesis of 3-deaza-3-nitro-2′-deoxyadenosine

Photoactivable deoxyadenosine mimic, 3-deaza-3-nitro-2′- deoxyadenosine (2), was prepared using two different synthetic routes. The first route involved base catalyzed glycosylation of 3-deaza-3-nitroadenine, which was prepared by regioselective nitration